Egrifta (Tesamorelin) Pre-Surgery Hold Window: What Clinicians Need to Know

Why Tesamorelin's Mechanism Makes Perioperative Timing Matter

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH) 1. It binds pituitary GHRH receptors, stimulating pulsatile GH secretion, which in turn raises hepatic and peripheral insulin-like growth factor-1 (IGF-1). That IGF-1 elevation is the primary driver of visceral fat reduction in HIV-associated lipodystrophy.

The same GH/IGF-1 axis, however, directly antagonizes insulin signaling. Elevated GH suppresses glucose uptake in skeletal muscle and promotes hepatic gluconeogenesis. Under the metabolic stress of surgery, anesthesia, and the post-operative catabolic state, this physiological antagonism can tip a compensated patient into clinically significant hyperglycemia or, in patients already on insulin, into unpredictable glycemic swings.

GH-Axis Physiology and Surgical Stress

Surgical trauma provokes a well-characterized neuroendocrine stress response: catecholamine surge, cortisol rise, and endogenous GH secretion. Layering exogenous GHRH stimulation on top of that stress response amplifies GH output in an additive, not simply redundant, fashion 2. The practical result is that patients who remain on tesamorelin through surgery face higher peak GH levels during the perioperative window than either their baseline or the surgery-induced level alone would predict.

Fluid Balance and Anesthetic Risk

GH excess is well known to cause sodium and water retention through IGF-1-mediated effects on renal tubular reabsorption 3. For patients undergoing procedures with significant fluid shifts (bowel resection, cardiac surgery, major orthopedic reconstruction), pre-existing GHRH stimulation could contribute to perioperative fluid overload, pulmonary edema, or delayed extubation. Holding tesamorelin 7 days ahead allows serum IGF-1 to return toward the patient's pre-treatment baseline, reducing this confounding variable.

The Evidence Base for Tesamorelin's Efficacy (and Why It Informs the Hold Decision)

The perioperative hold recommendation cannot be understood in isolation from the evidence that established tesamorelin's biological potency. If the drug had only modest GH-axis effects, a hold window would be less critical.

Falutz et al. 2007 (NEJM Landmark Trial)

In the phase 3 randomized controlled trial by Falutz et al. Published in the New England Journal of Medicine, 412 HIV-infected adults with abdominal lipodystrophy were randomized to tesamorelin 2 mg/day subcutaneous versus placebo for 26 weeks 1. Tesamorelin produced a 15.2% reduction in visceral adipose tissue (VAT) by CT measurement versus a 5.0% reduction in the placebo arm (P<0.001). IGF-1 levels rose by a mean of 136 ng/mL in the tesamorelin group at 26 weeks.

That 136 ng/mL IGF-1 increment is the clinically significant number for surgical planning. IGF-1 at those concentrations maintains measurable GH-counter-regulatory activity for approximately 5 to 7 days after the last injection, which is the biological basis for the minimum 7-day hold 1.

Phase 3 Extension: Glycemic Signal

A 52-week extension of the Falutz program showed that fasting glucose increased by a mean of 4.2 mg/dL in tesamorelin recipients compared with placebo 4. That increment is modest under outpatient conditions but becomes clinically relevant when combined with surgical stress hyperglycemia, which the Society for Ambulatory Anesthesia defines as glucose above 180 mg/dL intraoperatively 5. The additive effect is enough to push borderline patients across that threshold.

FDA Label Warnings Relevant to Surgery

The FDA-approved prescribing information for Egrifta (tesamorelin for injection) explicitly warns that tesamorelin may cause glucose intolerance and that patients with pre-existing diabetes require additional monitoring 6. The label does not specify a surgical hold duration (no GLP-1 or GH-analogue label does at present), but the glucose and fluid retention warnings are the pharmacological justification for the 7-day minimum recommended by institutional protocols.

Recommended Pre-Surgery Hold Protocol for Tesamorelin

No single FDA-mandated hold window exists in the Egrifta label as of January 2025. The 7-day minimum is derived from the drug's pharmacodynamic profile, IGF-1 half-life data, and analogy with recombinant human growth hormone perioperative guidance published by the Endocrine Society 7.

Step 1: Classify the Surgical Procedure

Not every procedure carries the same risk from GH-axis activation.

• Minor ambulatory procedures (skin biopsy, dental extraction, joint aspiration): A 3-day hold may be sufficient given the limited physiological stress and minimal fluid shifts.
• Intermediate procedures (laparoscopic cholecystectomy, hernia repair, moderate orthopedic work): Hold for 7 days. Obtain fasting glucose the morning of surgery.
• Major procedures (bowel resection, cardiovascular surgery, complex reconstructive surgery): Hold for 10 to 14 days preoperatively. Check IGF-1 level at hold initiation and again 24 to 48 hours before the scheduled procedure to confirm return toward baseline.

Step 2: Preoperative Laboratory Checks

Before stopping tesamorelin, document the patient's current glycemic status with a fasting glucose and HbA1c. This establishes the baseline against which perioperative glucose excursions will be judged and guides the anesthesia team's intraoperative glucose management protocol.

Patients on tesamorelin often carry a diagnosis of HIV and are managed with antiretroviral therapy (ART), some components of which (protease inhibitors in particular) independently impair insulin sensitivity 8. The surgical team needs to know the combined metabolic burden, not just tesamorelin's contribution.

Step 3: Communication With the Surgical and Anesthesia Teams

The prescribing clinician should send a brief perioperative summary to the operating surgeon and anesthesiologist at the time the hold is initiated. That summary should include:

1. Current tesamorelin dose and duration of therapy.
2. Most recent IGF-1 level and fasting glucose.
3. Confirmed last injection date.
4. Any concurrent medications that affect glucose (ART agents, corticosteroids, metformin).
5. Planned restart date and the clinical criteria that must be met before restart.

This communication prevents the surgical team from assuming the patient is simply "off a hormone injection" without understanding the GH-axis implications.

Postoperative Restart: Timing and Clinical Criteria

Restarting tesamorelin too early after surgery introduces the same fluid retention and glucose antagonism risks that motivated the pre-surgery hold. The general recommendation from endocrinology literature on GH-axis therapy is to wait until the catabolic stress response has resolved, wounds are healing without infection, and glycemic control is stable without escalated insulin requirements 7.

Minimum Restart Timeline

For intermediate and major procedures, a 10- to 14-day postoperative window before restarting tesamorelin at 2 mg/day is reasonable. For minor procedures with same-day discharge and no significant glycemic excursion, restart at 5 to 7 days is acceptable.

Clinical Criteria Before Restart

All four of the following criteria should be met before re-initiating the drug:

• Fasting glucose below 126 mg/dL on two consecutive readings or return to the patient's individual pre-surgical glycemic baseline.
• No active wound infection or dehiscence (IGF-1 may theoretically affect fibroblast proliferation rates, and introducing GH-axis stimulation into an actively infected wound has not been studied in this population).
• Stable or improving renal function (tesamorelin's fluid-retentive effects could worsen oliguria in the setting of post-surgical acute kidney injury).
• Confirmed oral intake sufficient to support subcutaneous injection site rotation and patient self-administration.

IGF-1 Monitoring at Restart

The Endocrine Society clinical practice guideline on GH therapy states that IGF-1 should be maintained within the age- and sex-adjusted normal range during treatment 7. Check IGF-1 four weeks after restarting tesamorelin post-surgery. A post-surgical IGF-1 that overshoots the upper limit of normal (ULN) may indicate altered GH-axis sensitivity during recovery and warrants a temporary dose reduction to 1 mg/day for four weeks before retitrating to 2 mg/day.

Special Populations Requiring Modified Hold Protocols

Patients With HIV and Diabetes

HIV-positive patients taking protease inhibitors and tesamorelin carry a compounded insulin-resistance burden. In the 52-week Falutz extension trial, the subgroup with pre-existing impaired fasting glucose at baseline showed a mean glucose increment of 8.1 mg/dL on tesamorelin versus 1.3 mg/dL in the non-impaired subgroup 4. That near-four-fold difference means diabetic patients on tesamorelin undergoing surgery need a 10-day minimum hold regardless of procedure complexity, along with intraoperative glucose monitoring every 60 minutes per the American Diabetes Association's Standards of Care 9.

Patients With Pre-Existing Edema or Heart Failure

GH-axis stimulation promotes renal tubular sodium reabsorption, expanding extracellular volume 3. Patients with NYHA Class II or higher heart failure who are on tesamorelin represent a high-risk perioperative cohort. The hold window for this group should extend to 14 days preoperatively, and the cardiac surgery team should be notified of the recent GH-axis stimulation history. Volume status assessment (BNP or NT-proBNP) at the preoperative visit is advisable.

Pediatric and Adolescent Patients

Tesamorelin is not FDA-approved for pediatric use 6. The perioperative guidance above applies to adults age 18 and older. Any off-label pediatric use should be managed by a pediatric endocrinologist before surgical procedures, and the surgical hold decision should be individualized based on IGF-1 levels and procedure type.

Drug Interactions That Complicate the Perioperative Hold

Several drug classes commonly used in the perioperative period interact pharmacodynamically with tesamorelin's GH-axis effects.

Corticosteroids

Glucocorticoids blunt GH secretion and oppose IGF-1 action at the receptor level 10. Patients who receive intraoperative or postoperative corticosteroids (dexamethasone for nausea prophylaxis, methylprednisolone for spinal cord protection) may see an attenuated rebound in IGF-1 when tesamorelin restarts. The restart IGF-1 check at four weeks is especially important for this subgroup.

Insulin and Oral Hypoglycemics

Because tesamorelin reduces insulin sensitivity, holding the drug predictably improves insulin sensitivity within 5 to 7 days. Patients on insulin or sulfonylureas who hold tesamorelin preoperatively may need their hypoglycemic doses adjusted downward by 10 to 15% during the hold period to avoid hypoglycemia before surgery 2.

Cyclosporine and Tacrolimus

For HIV patients who have undergone solid organ transplantation and are on calcineurin inhibitors, tesamorelin may affect cyclosporine pharmacokinetics indirectly through IGF-1-mediated changes in hepatic CYP3A4 activity. Transplant physicians should be informed of the hold-and-restart plan so trough monitoring can be intensified in the perioperative window.

Monitoring Summary Table

| Timepoint | Test | Action Threshold | |---|---|---| | Hold initiation (Day 0) | Fasting glucose, HbA1c, IGF-1 | Document baseline | | Day before surgery | Fasting glucose | Above 180 mg/dL: notify anesthesia | | Intraoperative (major surgery) | Glucose q60 min | Above 180 mg/dL: insulin protocol | | Post-op Day 1 to 3 | Fasting glucose daily | Trend toward pre-surgical baseline | | Post-op Day 10 to 14 (restart) | Fasting glucose, wound check | Meets restart criteria (see above) | | Post-restart Week 4 | IGF-1 | Within age/sex-adjusted normal range |

What the Evidence Does Not Yet Cover

The perioperative tesamorelin literature is thin. No randomized trial has specifically evaluated outcomes in tesamorelin patients who held versus continued the drug through surgery. The 7-day hold recommendation is built on pharmacodynamic logic (IGF-1 half-life, GH counter-regulatory physiology), analogy with rhGH perioperative data, and the FDA label's glucose and fluid warnings.

The Endocrine Society's 2011 clinical practice guideline on GH deficiency states: "We recommend against continuing GH therapy in the presence of active malignancy, critical illness, or major elective surgery until recovery is complete" 7. Although tesamorelin is not recombinant human GH, it produces an equivalent downstream GH/IGF-1 signal, and most endocrinologists apply the same principle by analogy.

A prospective registry study of tesamorelin users undergoing elective surgery would resolve the uncertainty. Until that data exists, the 7-day minimum hold remains the standard institutional practice at centers managing HIV lipodystrophy patients.

Clinical Bottom Line for Prescribers

Stop tesamorelin a minimum of 7 days before any intermediate or major elective surgery. Extend the hold to 10 to 14 days for major procedures, diabetic patients, or those with pre-existing fluid retention. Document fasting glucose and IGF-1 at hold initiation, communicate the hold plan to the surgical and anesthesia teams, and restart at 2 mg/day subcutaneous only after fasting glucose has returned to the patient's individual baseline and wounds show no signs of infection. Check IGF-1 four weeks post-restart to confirm the level remains within the age-adjusted normal range per Endocrine Society guidance 7.